ArticleTranslational cancer research2025
Long-term partial response after camrelizumab plus chemotherapy induction therapy and camrelizumab maintenance therapy beyond two years in squamous non-small cell lung cancer: a case report.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Camrelizumab-induced intranasal hemangioma in a patient with hepatocellular carcinoma: a case report.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have become the standard first-line treatment for non-oncogene-addicted advanced squamous non-small cell lung cancer (NSCLC). Here we report the first case of a squamous NSCLC patient without a complete response (CR) from ICI-based first-line therapy and remained progression-free after with more than 2 years of continued camrelizumab. Case Description: A 62-year-old man was found to have multiple pulmonary nodules and a 4.2 cm × 3.1 cm soft-tissue mass adjacent to the pulmonary artery on routine imaging in May 2021. He had a 37-year history of smoking and no significant comorbidities. Contrast-enhanced computed tomography (CT) revealed a 4.4 cm × 2.8 cm mass near the left-upper hilar region and multiple small bilateral pulmonary nodules. Brain magnetic resonance imaging, abdominal CT, and bone scan showed no distant metastasis. CT-guided biopsy confirmed poorly differentiated squamous cell carcinoma. Immunohistochemistry was positive for P40 and CK5/6, with a Ki-67 index of 50%. The patient was diagnosed with cT2bN0Mx squamous NSCLC, and began first-line treatment in June 2021 with camrelizumab (200 mg), paclitaxel (300 mg), and carboplatin (400 mg), administered every 21 days. After two cycles, a partial response (PR) was achieved. He completed six cycles of combination therapy by December 2021. During treatment, he developed reactive capillary hemangiomas related to camrelizumab, which was resolved after temporary discontinuation and thalidomide. Due to the coronavirus disease 2019 pandemic, camrelizumab maintenance therapy was administered every 1-2 months from October 2021 to April 2024. Imaging in November 2024 showed a stable soft-tissue shadow and small nodules without clear progression. As of July 2025, the patient remained progression-free, with a duration of response of 49 months since his initial PR. Conclusions: For squamous NSCLC patients without a CR to induction therapy, continuing ICI maintenance therapy beyond 2 years-rather than discontinuing treatment-may potentially extend overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.